540776-26-9

Upstream product

• 540776-16-7 (2'S,3'S)-methyl 3,4-O-[2',3'-dimethoxybutane-2',3'-diyl]-2,6-bis(O-toluene-p-sulfonyl)-α-D-mannopyranoside 
• 540776-21-4 methyl 3,4-di-O-benzoyl-6-deoxy-6-iodo-2-O-toluene-p-sulfonyl-α-D-glucopyranoside 
• 617-04-9 (2R,3S,4S,5S,6S)-2-(hydroxymethyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 98-88-4 benzoyl chloride 
• 540776-19-0 methyl 6-deoxy-6-iodo-2-O-toluene-p-sulfonyl-α-D-glucopyranoside 
• 540776-23-6 (2S,3S,4R)-3,4-bis-O-benzoyloxy-2-O-toluene-p-sulfonylhex-5-enal 
• 540776-17-8 (2'S,3'S)-methyl 6-deoxy-3,4-O-[2',3'-dimethoxybutane-2',3'-diyl]-6-iodo-2-O-toluene-p-sulfonyl-α-D-mannopyranoside 

Downstream Products

• 540776-10-1 (1S)-2-exo,3-endo-2,3-dihydroxy-4-endo-4-hydroxymethyl-6-azabicyclo[3.1.0]hexane 
• 540776-28-1 (1S)-N-benzyl-2-exo,3-endo-2,3-dihydroxy-4-endo-4-hydroxymethyl-6-azabicyclo[3.1.0]hexane 

Relevant academic research and scientific papers

Aziridines as a structural motif to conformational restriction of azasugars.

In order to investigate the hypothesis that the glycosidase inhibitor isofagomine was bound to alpha- or beta-glucosidase in a 1,4B conformation, a number of bicyclic aziridines that adopt the 1,4B or B1,4 conformations were synthesised and investigated. (1R)-2-endo,3-exo-2,3-Dihydroxy-4-endo-4-hydroxymethyl-6- azabicyclo[3.1.0]hexane (5) and its N-methyl and N-benzyl analogues and (1S)-2-exo-3-endo-2,3-dihydroxy-4- endo-4-hydroxymethyl-6-azabicyclo-[3.1.0]hexane (6) were synthesised. The aziridines 5 and 6 were found to be weak or not inhibitors of alpha-glucosidase, beta-glucosidase and alpha-fucosidase.